Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion. The approval marks a critical step in scaling production to meet anticipated demand in Europe, where the company plans to launch GelrinC commercially.
The significance of this approval lies in its potential to address a substantial unmet medical need. According to the company, approximately 470,000 cases for cartilage knee repair occur annually in the U.S. alone, where no off-the-shelf treatment is available. GelrinC is designed as a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The new manufacturing process enhances the company's ability to produce sufficient quantities for the market while reducing environmental impact and improving worker safety.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue including inflamed cartilage and bone. The company’s lead product, GelrinC, represents a potential breakthrough in orthopedic treatments, offering a minimally invasive option for patients suffering from cartilage defects.
For more information, the full press release is available at https://ibn.fm/Ths4h. Latest news and updates relating to RGNT can be found in the company’s newsroom at https://ibn.fm/RGNT.
